Lonza unveils plan for $218M small molecule manufacturing facility in Switzerland

[cafead]

via Switzerland’s Lonza has been hard at work ramping up its manufacturing capabilities for a handful of COVID-19 products, including a decade-long deal to produce Moderna’s mRNA vaccine. Now, the CDMO giant is adding oncology to its to-do list and will build a brand new small molecule facility with the help of an undisclosed “biopharmaceutical partner.”

article source